Retraction: Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector (PLoS ONE (2013) 8:10 (e78521) DOI: 10.1371/journal.pone.0078521);Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Khattar, Sunil K ^a   Samal, Sweety ^a   LaBranche, Celia C ^b   Montefiori, David C ^b   Collins, Peter L ^c   Samal, Siba K ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b DUKE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 140L; GLYCOPROTEIN GP 140S; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NEWCASTLE DISEASE PARAMYXOVIRUS VECTOR; OLIGOMER; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE DELETION; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; TH1 CELL; TH1 TH2 BALANCE; VIRUS RECOMBINANT; VIRUS STRAIN;

CAVIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; NEWCASTLE DISEASE VIRUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GENE EXPRESSION; GENETIC VECTORS; GUINEA PIGS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; NEWCASTLE DISEASE VIRUS; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; VACCINES, ATTENUATED;

EID: 84884858409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0244046     Document Type: Erratum

References (57)

1. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, et al. (2000) Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6: 200-206. doi:10.1038/72309. PubMed: 10655110.
2. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-210. doi:10.1038/72318. PubMed: 10655111.
3. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, et al. (2012) Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481: 81-84. doi:10.1038/nature10660. PubMed: 22139420.
4. Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, et al. (2013) Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001). J Infect Dis 207: 248-256. doi:10.1093/infdis/jis671. PubMed: 23125443.
5. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, et al. (2012) The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 188: 5166-5176. doi:10.4049/jimmunol.1102756. PubMed: 22529301.
6. Franzusoff A, Volpe AM, Josse D, Pichuantes S, Wolf JR, (1995) Biochemical and genetic definition of the cellular protease required for HIV-1 gp160 processing. J Biol Chem 270: 3154-3159. doi:10.1074/jbc.270.7.3154. PubMed: 7852398.
7. Decroly E, Vandenbranden M, Ruysschaert JM, Cogniaux J, Jacob GS, et al. (1994) The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-1 SU) and gp41 (HIV-I TM). J Biol Chem 269: 12240-12247. PubMed: 8163529.
8. Helseth E, Olshevsky U, Furman C, Sodroski J, (1991) Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol 65: 2119-2123. PubMed: 2002555.
9. Pierson TC, Doms RW, (2003) HIV-1 entry and its inhibition. Curr Top Microbiol Immunol 281: 1-27. doi:10.1007/978-3-642-19012-4_1. PubMed: 12932074.
10. Robert-Guroff M, (2007) Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 18: 546-556. doi:10.1016/j.copbio.2007.10.010. PubMed: 18063357.
11. Phogat S, Wyatt R, (2007) Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr Pharm Des 13: 213-227. doi:10.2174/138161207779313632. PubMed: 17269929.
12. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671. doi:10.1086/508748. PubMed: 17109337.
13. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236. doi:10.1038/ni0304-233. PubMed: 14985706.
14. Schülke N, Vesanen MS, Sanders RW, Zhu P, Lu M, et al. (2002) Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol 76: 7760-7776. doi:10.1128/JVI.76.15.7760-7776.2002. PubMed: 12097589.
15. Srivastava IK, Stamatatos L, Kan E, Vajdy M, Lian Y, et al. (2003) Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 77: 11244-11259. doi:10.1128/JVI.77.20.11244-11259.2003. PubMed: 14512572.
16. Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, et al. (2002) Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 76: 4634-4642. doi:10.1128/JVI.76.9.4634-4642.2002. PubMed: 11932429.
17. Zhang PF, Cham F, Dong M, Choudhary A, Bouma P, et al. (2007) Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A 104: 10193-10198. doi:10.1073/pnas.0608635104. PubMed: 17540729.
18. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, et al. (2000) A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74: 627-643. doi:10.1128/JVI.74.2.627-643.2000. PubMed: 10623724.
19. Du SX, Idiart RJ, Mariano EB, Chen H, Jiang P, et al. (2009) Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein. Virology 395: 33-44. doi:10.1016/j.virol.2009.07.042. PubMed: 19815247.
20. Krishnamurthy S, Samal SK, (1998) Nucleotide sequences of the trailer, nucleocapsid protein gene and intergenic regions of Newcastle disease virus strain Beaudette C and completion of the entire genome sequence. J Gen Virol 79(Pt 10):: 2419-2424. PubMed: 9780047.
21. Bukreyev A, Huang Z, Yang L, Elankumaran S, St Claire M, et al. (2005) Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol 79: 13275-13284. doi:10.1128/JVI.79.21.13275-13284.2005. PubMed: 16227250.
22. DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, et al. (2007) Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A 104: 9788-9793. doi:10.1073/pnas.0703584104. PubMed: 17535926.
23. DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, et al. (2010) Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 29: 17-25. doi:10.1016/j.vaccine.2010.10.024. PubMed: 21034822.
24. DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, et al. (2010) Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 84: 1489-1503. doi:10.1128/JVI.01946-09. PubMed: 19923177.
25. Carnero E, Li W, Borderia AV, Moltedo B, Moran T, et al. (2009) Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J Virol 83: 584-597. doi:10.1128/JVI.01443-08. PubMed: 19004953.
26. Maamary J, Array F, Gao Q, García-Sastre A, Steinman RM, et al. (2011) Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice. J Virol 85: 2235-2246. doi:10.1128/JVI.02036-10. PubMed: 21159873.
27. Khattar SK, Samal S, Devico AL, Collins PL, Samal SK, (2011) Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. J Virol 85: 10529-10541. PubMed: 21849467.
28. Huang Z, Krishnamurthy S, Panda A, Samal SK, (2001) High-level expression of a foreign gene from the most 3'-proximal locus of a recombinant Newcastle disease virus. J Gen Virol 82: 1729-1736. PubMed: 11413385.
29. Huang Z, Krishnamurthy S, Panda A, Samal SK, (2003) Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J Virol 77: 8676-8685. doi:10.1128/JVI.77.16.8676-8685.2003. PubMed: 12885886.
30. Krishnamurthy S, Huang Z, Samal SK, (2000) Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 278: 168-182. doi:10.1006/viro.2000.0618. PubMed: 11112492.
31. Alexander DJ, (1997) Newcastle disease and other avian Paramyxoviridae infection. Ames, IA: Iowa State University Press.
32. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125. doi:10.1128/JVI.79.16.10108-10125.2005. PubMed: 16051804.
33. Folks T, Benn S, Rabson A, Theodore T, Hoggan MD, et al. (1985) Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci U S A 82: 4539-4543. doi:10.1073/pnas.82.13.4539. PubMed: 2989831.
34. Kim JH, Pitisuttithum P, Kamboonruang C, Chuenchitra T, Mascola J, et al. (2003) Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1. AIDS Res Hum Retroviruses 19: 807-816.
35. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, et al. (2012) Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206: 431-441. doi:10.1093/infdis/jis367. PubMed: 22634875.
36. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220. doi:10.1056/NEJMoa0908492. PubMed: 19843557.
37. Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, et al. (1998) Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis 177: 310-319. doi:10.1086/514209. PubMed: 9466516.
38. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, et al. (1996) Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 173: 340-348. doi:10.1093/infdis/173.2.340. PubMed: 8568294.
39. Matthews TJ, (1994) Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retrovir 10: 631-632. doi:10.1089/aid.1994.10.631. PubMed: 8074926.
40. Chakrabarti BK, Kong WP, Wu BY, Yang ZY, Friborg J, et al. (2002) Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 76: 5357-5368. doi:10.1128/JVI.76.11.5357-5368.2002. PubMed: 11991964.
41. Bültmann A, Muranyi W, Seed B, Haas J, (2001) Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression. J Virol 75: 5263-5276. doi:10.1128/JVI.75.11.5263-5276.2001. PubMed: 11333908.
42. Bu Z, Ye L, Vzorov A, Taylor D, Compans RW, et al. (2004) Enhancement of immunogenicity of an HIV Env DNA vaccine by mutation of the Tyr-based endocytosis motif in the cytoplasmic domain. Virology 328: 62-73. doi:10.1016/j.virol.2004.06.041. PubMed: 15380359.
43. Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, et al. (2007) A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360: 329-340. doi:10.1016/j.virol.2006.10.032. PubMed: 17126869.
44. Yang X, Wyatt R, Sodroski J, (2001) Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 75: 1165-1171. doi:10.1128/JVI.75.3.1165-1171.2001. PubMed: 11152489.
45. Bower JF, Yang X, Sodroski J, Ross TM, (2004) Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol 78: 4710-4719. doi:10.1128/JVI.78.9.4710-4719.2004. PubMed: 15078953.
46. Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J, et al. (2012) HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A 109: 12111-12116. doi:10.1073/pnas.1204533109. PubMed: 22773820.
47. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908. doi:10.1126/science.1111781. PubMed: 15860590.
48. Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, et al. (2008) Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 373: 72-84. doi:10.1016/j.virol.2007.11.005. PubMed: 18155743.
49. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406-412. doi:10.1038/nature11544. PubMed: 23151583.
50. Porichis F, Kaufmann DE, (2011) HIV-specific CD4 T cells and immune control of viral replication. Curr Opin HIV AIDS 6: 174-180. doi:10.1097/COH.0b013e3283454058. PubMed: 21502921.
51. Blankson JN, (2010) Control of HIV-1 replication in elite suppressors. Discov Med 9: 261-266. PubMed: 20350494.
52. Demers KR, Reuter MA, Betts MR, (2013) CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis. Immunol Rev 254: 190-206. doi:10.1111/imr.12069. PubMed: 23772621.
53. Picker LJ, Hansen SG, Lifson JD, (2012) New paradigms for HIV/AIDS vaccine development. Annu Rev Med 63: 95-111. doi:10.1146/annurev-med-042010-085643. PubMed: 21942424.
54. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, et al. (2004) Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18: 1213-1216. doi:10.1097/00002030-200405210-00019. PubMed: 15166541.
55. Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, et al. (1991) Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337: 567-572. doi:10.1016/0140-6736(91)91636-9. PubMed: 1671940.
56. Papp Z, Babiuk LA, Baca-Estrada ME, (1999) The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1. Vaccine 17: 933-943. doi:10.1016/S0264-410X(98)00279-5. PubMed: 10067700.
57. Pulendran B, Ahmed R, (2011) Immunological mechanisms of vaccination. Nat Immunol 12: 509-517. PubMed: 21739679.